第一篇：醫(yī)藥學(xué)專業(yè)自我介紹

醫(yī)藥學(xué)專業(yè)自我介紹(精選多篇)

好范文為大家整理了以下這一份關(guān)于醫(yī)藥學(xué)專業(yè)畢業(yè)生的自我鑒定范文，僅供廣大畢業(yè)生前來參考一下。

由于經(jīng)過一個學(xué)期的學(xué)習(xí)，我知道了醫(yī)學(xué)理論學(xué)作為醫(yī)學(xué)與理論學(xué)相交叉的邊緣學(xué)科，其宗旨在于提高學(xué)生的醫(yī)學(xué)人文素質(zhì)和綜合職業(yè)素質(zhì)，再加上后來的實踐活動使理論更加與實際的緊密聯(lián)系，令我認(rèn)為學(xué)習(xí)醫(yī)學(xué)理論學(xué)成為醫(yī)學(xué)生一門必須學(xué)習(xí)的課程。

在“藥學(xué)中西、醫(yī)學(xué)濟(jì)世”八字校風(fēng)的鞭策下，我努力學(xué)習(xí)，刻苦鉆研、勇于進(jìn)取，時刻向“將自己培養(yǎng)成為具備高綜合素質(zhì)的臨床藥學(xué)畢業(yè)生”的目標(biāo)奮進(jìn)。我還獲得了學(xué)校三好學(xué)生和二等獎

學(xué)金等重要獎項。學(xué)習(xí)當(dāng)中我深深的體會到，我們以履行公民義務(wù)為光榮，本著社會共濟(jì)、關(guān)愛他人的精神，用愛心共同托起生命的希望。血液是生命的源泉，愛是生命的曙光。生命之源聯(lián)系著你、我、他，我們的愛心是無限的。

所以在有限的學(xué)習(xí)期間，我在學(xué)校形成尊重勞動、尊重知識，培養(yǎng)德、智、體、美全面發(fā)展的高素質(zhì)學(xué)生，注重學(xué)術(shù)的理念：崇尚學(xué)術(shù)，營造發(fā)揚(yáng)學(xué)術(shù)民主和學(xué)術(shù)自由、重視學(xué)術(shù)成就的濃郁學(xué)術(shù)氛圍。只有堅持這種理念，才能不斷取得科學(xué)研究的豐碩成果，才能不斷提高自身的學(xué)術(shù)水平和知識質(zhì)量，知識創(chuàng)新和文化傳播等做出應(yīng)有貢獻(xiàn)。

花蕾要綻放，不是在溫室，而是在肥沃的土壤上吸收天地日月精華，經(jīng)受風(fēng)霜雨雪考驗。我要成才，我必須在廣闊天地里自我歷練，真正在熟悉自我、完善自我、熟悉社會、服務(wù)社會的社會實踐中成長為社會英才。只有熟悉了自我，完善了自我，才能更好地熟悉社會，服務(wù)社會;只有在熟悉社會、服務(wù)社會的過程里才能更好地熟悉自我、完善自我。

在往后的學(xué)習(xí)中，我會更加努力，我會牢記著醫(yī)學(xué)生的誓詞：我自愿獻(xiàn)身醫(yī)藥學(xué)，熱愛祖國，忠于人民，恪守藥德，尊師守紀(jì)，刻苦鉆研，孜孜不倦，精益求精，面發(fā)展。我決心竭盡全力除人類之病痛，助健康之完美，維護(hù)醫(yī)術(shù)的圣潔和榮譽(yù)，救死扶傷，不辭艱辛，執(zhí)著追求，為祖國醫(yī)藥衛(wèi)生事業(yè)的發(fā)展和人類身心健康奮斗終生。

下面就一起來欣賞以下這一份關(guān)于醫(yī)藥學(xué)專業(yè)學(xué)習(xí)的自我鑒定范文，歡迎大家瀏覽。

由于經(jīng)過一個學(xué)期的學(xué)習(xí)，我知道了醫(yī)學(xué)理論學(xué)作為醫(yī)學(xué)與理論學(xué)相交叉的邊緣學(xué)科，其宗旨在于提高學(xué)生的醫(yī)學(xué)人文素質(zhì)和綜合職業(yè)素質(zhì)，再加上后來的實踐活動使理論更加與實際的緊密聯(lián)系，令我認(rèn)為學(xué)習(xí)醫(yī)學(xué)理論學(xué)成為醫(yī)學(xué)生一門必須學(xué)習(xí)的課程。

在“藥學(xué)中西、醫(yī)學(xué)濟(jì)世”八字校風(fēng) 的鞭策下，我努力學(xué)習(xí)，刻苦鉆研、勇于進(jìn)取，時刻向“將自己培養(yǎng)成為具備高綜合素質(zhì)的臨床藥學(xué)畢業(yè)生”的目標(biāo)奮進(jìn)。我還獲得了學(xué)校三好學(xué)生和二等獎學(xué)金等重要獎項。學(xué)習(xí)當(dāng)中我深深的體會到，我們以履行公民義務(wù)為光榮，本著社會共濟(jì)、關(guān)愛他人的精神，用愛心共同托起生命的希望。血液是生命的源泉，愛是生命的曙光。生命之源聯(lián)系著你、我、他，我們的愛心是無限的。

所以在有限的學(xué)習(xí)期間，我在學(xué)校形成尊重勞動、尊重知識，培養(yǎng)德、智、體、美全面發(fā)展的高素質(zhì)學(xué)生，注重學(xué)術(shù)的理念：崇尚學(xué)術(shù)，營造發(fā)揚(yáng)學(xué)術(shù)民主和學(xué)術(shù)自由、重視學(xué)術(shù)成就的濃郁學(xué)術(shù)氛圍。只有堅持這種理念，才能不斷取得科學(xué)研究的豐碩成果，才能不斷提高自身的學(xué)術(shù)水平和知識質(zhì)量，知識創(chuàng)新和文化傳播等做出應(yīng)有貢獻(xiàn)。

花蕾要綻放，不是在溫室，而是在肥沃的土壤上吸收天地日月精華，經(jīng)受風(fēng)霜雨雪考驗。我要成才，我必須在廣

闊天地里自我歷練，真正在熟悉自我、完善自我、熟悉社會、服務(wù)社會的社會實踐中成長為社會英才。只有熟悉了自我，完善了自我，才能更好地熟悉社會，服務(wù)社會;只有在熟悉社會、服務(wù)社會的過程里才能更好地熟悉自我、完善自我。

在往后的學(xué)習(xí)中，我會更加努力，我會牢記著醫(yī)學(xué)生的誓詞：我自愿獻(xiàn)身醫(yī)藥學(xué)，熱愛祖國，忠于人民，恪守藥德，尊師守紀(jì)，刻苦鉆研，孜孜不倦，精益求精，面發(fā)展。我決心竭盡全力除人類之病痛，助健康之完美，維護(hù)醫(yī)術(shù)的圣潔和榮譽(yù)，救死扶傷，不辭艱辛，執(zhí)著追求，為祖國醫(yī)藥衛(wèi)生事業(yè)的發(fā)展和人類身心健康奮斗終生。

下面就一起來欣賞以下這一份關(guān)于醫(yī)藥學(xué)本科畢業(yè)生的優(yōu)秀自我評價范文，歡迎廣大畢業(yè)生瀏覽。

驀然回首四年大學(xué)生活，當(dāng)年單純懵懂的少年已成成熟穩(wěn)重之人，使我有此巨變的正是那段不凡的人生經(jīng)歷以及其對夢想堅持不懈的努力。

本人努力學(xué)習(xí)，刻苦鉆研、勇于進(jìn)取。在四年里，曾當(dāng)任過班長、學(xué)生會學(xué)習(xí)部部委、學(xué)生社團(tuán)聯(lián)合會文化部部長等校內(nèi)重要學(xué)生干部，曾多次參加過大量的校內(nèi)外的活動，由于成績突出，本人還獲得了學(xué)校三好學(xué)生和二等獎學(xué)金等重要獎項。尊敬老師，團(tuán)結(jié)同學(xué)，在校內(nèi)擁有廣泛的群眾基礎(chǔ)。

在兼顧學(xué)業(yè)的前提下，還不忘對自身能力的培養(yǎng)，積極參加各種校內(nèi)校外的培訓(xùn)，拓寬了眼界的同時，積累了大量的社會實踐經(jīng)驗，使德智體得到全面的發(fā)展。在實習(xí)期間，持著主動求學(xué)的學(xué)習(xí)態(tài)度，我積極向帶教老師學(xué)習(xí)，秉著“健康所系性命相托”的信念，孜孜不倦地吸收醫(yī)藥學(xué)知識，為日后的學(xué)習(xí)、工作打下堅實的基礎(chǔ)。由于工作認(rèn)真，表現(xiàn)出色，得到科室的一致好評。

我將在以后的工作和學(xué)習(xí)中更加努力，不斷充實自我、完善自我，刻苦鉆研，孜孜不倦，精益求精，竭盡全力除人類之病痛，為祖國醫(yī)藥衛(wèi)生事業(yè)的

發(fā)展和人類身心健康奮斗終生。

1.introduction to quantitative risk assessment

2.risk analysis is a valuable tool in the management of

microbial food safety issues and can provide a systematic

approach for the regulatory authorities and the food industry

to control the risk posed by a pathogen in a particular

food commodity.risk analysis consists of three elements:

risk assessment, risk management and risk communication.risk assessment is the scientific part of the process in which

the hazards are identified and the risk posed by that particular

hazard is calculated.the principles of

risk assessment including the four stages involved are outlined by the codex

alimentarius commission.each of the stages is summarised below.1.1.hazard identification

a hazard is defined as an agent having an adverse effect

on the public health of the human population and may

pose a short term, chronic, or fatal risk to a person.the

identification of microbial hazard associated with a particular

food is generally based on information generated from

routine microbial analysis of the commodity or from an

epidemiological linkage of a particular pathogen with a

case of food borne infection.1.2.exposure assessment

exposure assessment is a quantitative estimation of the

presence of a contaminant in a serving of food at the time

of consumption, or as close to this stage as is scientifically

possible and practical.however, the final estimation of the numbers and prevalence of a pathogen in the food is of ten

based on an accumulation of data on the prevalence and

numbers of pathogen at key points in the food chain with

data included on how particular stages in the food chain

affect the numbers/prevalence of the pathogen.the final

step in the process estimates the amount of contaminant

in a single serving, with information on the typical amount

of food consumed in a serving procured from nutritional

databases.the exposure assessment model can be ‘deterministic’，i.e.derived using single data points along the food chain.however, this approach may result in outlier values being

ignored and thus under or overestimating the risk.a more

common approach is to use a probablistic or stochastic

analysis, in which a distribution curve representing all data

is used as opposed to a single point estimate.typically a

monte carlo analysis is used to include data from all the

distributions along the chain and is done using software

such as @risk.in these analyses, a

single data point is chosen at random from each distribution

curve and used to calculate an outcome.the process

is repeated several thousand times with

a different data point in each distribution chosen each time

and with the final output being based on all the iterations.the error in the predicted risk may be due to variability or

uncertainty, and there is increasing emphasis being placed

on quantifying and separating the impact of both uncertainty

and variability in risk assessments.1.3.hazard characterisation

hazard characterisation relates exposure to a hazard

with the probable public health outcome.a

dose–response relationship can be used to estimate the

amount of pathogens which causes illness.the

data used in generating dose–response models are derived

from a variety of sources including human clinical trials，epidemiological studies based on food poisoning outbreaks，animal clinical trials, in vitro studies using cell lines，biomarkers or expert opinion.in some cases, the dose–

responses will describe the susceptibility of different populations，i.e.general population and immunocompromised.1.4.risk characterisation

the final stage in the process estimates the adverse

public health effect, or risk as a

consequence of exposure

to the hazard.this may be a prediction of illness per typical

serving or calculated as an annual risk of illness.depending on the hazard characterisation data available，the risk estimates may be broken down into age categories，based on differences in immune status in order to

identify groups which may be at higher risk following

exposure to the contaminant.the risk characterisation

model is generally developed using commercial software such as @risk or crystal ball.these programs can separate the distribution

for the overall risk prediction into uncertainty and variability

to allow more complex risk

estimation and analyses

of the data.the generated model can be used to assess

which parts of the chain significantly affect risk or to

assess the changes in predicted illness by incorporation

of a new hypothetical risk mitigation strategy at a particular

point in the chain.this paper reviews escherichia coli o157:h7 in the farm

to fork beef chain and examines how quantitative risk

assessment models have been applied to establish and manage

the risk posed.while other serovars of verocytotoxigenic

e.coli

are now emerging as a cause of similar illness to e.coli

o157:h7 they are not addressed in

this paper as there is

still limited information on their transmission thorough

the beef chain and they have not been included in any published

quantitative risk assessment models.2.e.coli o157:h7: human clinical aspects

e.coli o157 is a member of the enterhaemorrhagic

group of e.coli and was first implicated in infectious

disease in the early 1980s.the

symptoms of infection include bloody diarrhoea and severe

abdominal pain.haemolytic uraemic syndrome , a

cause of acute renal failure, may be a complication of the

illness, and neurological problems in the form of thrombotic

thrombocytopaenic purpura may

also occur.immuno-compromised patients, including young children

and the elderly, are at particular risk of developing hus.the time from exposure to onset of symptoms ranges from to 14 days.however, with complications the

illness may last many months and lead to permanent damage

or even death.pathogenicity is related to the ability of

the organism to adhere to and colonise the human large

intestinal epithelial tissue, forming attachment and effacing

lesions and the production of verocytotoxins.the

e.coli verocytotoxins are closely related to the shiga toxin

of shigella dysenteriae and are

typically bacteriophage

encoded.there are two main classes of verotoxin: vt1, a

homogeneous group of toxins, virtually identical to the

shiga toxin of shigella and vt2, a heterogeneous group

of toxins, more distantly related to the shiga toxin.e.coli o157 with the eae gene and vt2 are most often

associated with hus in patients.outbreaks of vtec infections involving serovar o157

have now been reported from united states and canada

bell et al., asia , australia , europe , and africa.however, the majority of cases

are sporadic and contribute significantly to overall cases

of infection.there is considerable

variation in infection

rates between different geographical regions.in europe, the

highest rates of infection are in scotland with approximately 4 cases per 100,000.in the republic of ireland

the incidence per 100,000 has ranged from a peak of

2.2 in 2014 to 1.3 in 2014.in northern europe

infection rates are very low ranging from 0.04 per

100,000 in norway and finland to 1.1 in denmark in

2014 although denmark has in 2014, reported its first general

outbreak of e.coli o157 attributed to contaminated

milk.in 2014, the incidence rate for

e.coli o157:h7 in north america was 0.9, a drop from

1.1 cases in 2014.in asia, japan has experienced the most

problems related to e.coli o157:h7 with an average incidence

rate of 2.74 per 100,000 between 1999 and 2014

.a number of sources

and reservoirs of e.coli o157 including beef and lamb，lettuce, sprouts, fruit juices, vegetables, raw milk, water

have been implicated as vehicles of transmission.person-to-person

is also an important mode of transmission, particularly

in day care centers and direct contact

with animals carrying the organism or with faecally

contaminated mud

are also recognised sources of infection

二、名詞術(shù)語

醫(yī)學(xué)及藥學(xué)名詞應(yīng)使用全國自然科學(xué)名詞審定委員會公布的規(guī)范名詞為準(zhǔn)。

1.現(xiàn)將常易出錯的不規(guī)范名詞糾正如下。

氨基酸轉(zhuǎn)移酶細(xì)胞紅細(xì)胞

作用機(jī)制側(cè)支循環(huán)綜合征

膽固醇單核－吞噬細(xì)胞系統(tǒng)

低鉀血癥高脂血癥內(nèi)鏡

固醇發(fā)紺反胃

分枝桿菌肺源性肺梗死

腦出血腦梗死心肌梗死

腦卒中放射性核素功能

肝硬化核糖體晶狀體

膠原纖維假膜咳痰

咯血抗生素磷脂酰膽堿

黏膜清蛋白期前收縮

妊娠高血壓綜合征三酰甘油

腎衰竭食欲缺乏食管

嗜酸性細(xì)胞性白細(xì)胞）同工酶

糖原畏食糖皮質(zhì)激素

圍生期下丘腦心排出量

心源性血紅蛋白血流動力學(xué) 藥源性醫(yī)源性真菌 原發(fā)性高血壓

第二篇：英語醫(yī)藥學(xué)專業(yè)

1.Introduction to quantitative risk assessment

2.Risk analysis is a valuable tool in the management of

microbial food safety issues and can provide a systematic

approach for the regulatory authorities and the food industry

to control the risk posed by a pathogen in a particular

food commodity.Risk analysis consists of three elements:

risk assessment, risk management and risk communication.Risk assessment is the scientific part of the process in which

the hazards are identified and the risk posed by that particular

hazard(i.e.pathogen)is calculated.The principles of

risk assessment including the four stages involved(hazard

identification, exposure assessment, hazard characterisation

and risk characterisation)are outlined by the Codex

Alimentarius Commission(Codex, 1999).Each of the stages is summarised below.1.1.Hazard identification

A hazard is defined as an agent having an adverse effect

on the public health of the human population and may

pose a short term, chronic, or fatal risk to a person.The

identification of microbial hazard associated with a particular

food is generally based on information generated from

routine microbial analysis of the commodity or from an

epidemiological linkage of a particular pathogen with a

case of food borne infection.1.2.Exposure assessment

Exposure assessment is a quantitative estimation of the

presence of a contaminant in a serving of food at the time

of consumption, or as close to this stage as is scientifically

possible and practical.However, the final estimation of the numbers and prevalence of a pathogen in the food is of ten

based on an accumulation of data on the prevalence and

numbers of pathogen at key points in the food chain with

data included on how particular stages in the food chain

affect the numbers/prevalence of the pathogen.The final

step in the process estimates the amount of contaminant

in a single serving, with information on the typical amount

of food consumed in a serving procured from nutritional

Databases.The exposure assessment model can be ‘deterministic’,i.e.derived using single data points along the food chain.However, this approach may result in outlier values being

ignored and thus under or overestimating the risk.A more

common approach is to use a probablistic or stochastic

analysis, in which a distribution curve representing all data

is used as opposed to a single point estimate.Typically a

Monte Carlo analysis is used to include data from all the

distributions along the chain and is done using software

such as @Risk(Palisade, NY, USA).In these analyses, a

single data point is chosen at random from each distribution

curve and used to calculate an outcome.The process

is repeated several thousand times(multiple iterations)with

a different data point in each distribution chosen each time

and with the final output being based on all the iterations.The error in the predicted risk may be due to variability or

uncertainty, and there is increasing emphasis being placed

on quantifying and separating the impact of both uncertainty

and variability in risk assessments(Cohen, Lampson,& Bowers, 1996;Pouillot, Beaudeau, Denis, &

Derouin, 2004).1.3.Hazard characterisation

Hazard characterisation relates exposure to a hazard

with the probable public health outcome(illness/death).A

dose–response relationship can be used to estimate the

amount(number)of pathogens which causes illness.The

data used in generating dose–response models are derived

from a variety of sources including human clinical trials,epidemiological studies based on food poisoning outbreaks,animal clinical trials, in vitro studies using cell lines,biomarkers or expert opinion.In some cases, the dose–

responses will describe the susceptibility of different populations,i.e.general population and immunocompromised.1.4.Risk characterisation

The final stage in the process estimates the adverse

public health effect, or risk as a consequence of exposure

to the hazard.This may be a prediction of illness per typical

serving or calculated as an annual risk of illness.Depending on the hazard characterisation data available,the risk estimates may be broken down into age categories,based on differences in immune status in order to

identify groups which may be at higher risk following

exposure to the contaminant.The risk characterisation

model is generally developed using commercial software such as @Risk or Crystal Ball(Decisioneering Inc., Denver,USA).These programs can separate the distribution

for the overall risk prediction into uncertainty and variability

to allow more complex risk estimation and analyses

of the data.The generated model can be used to assess

which parts of the chain significantly affect risk or to

assess the changes in predicted illness by incorporation

of a new hypothetical risk mitigation strategy at a particular

point in the chain.This paper reviews Escherichia coli O157:H7 in the farm

to fork beef chain and examines how quantitative risk

assessment models have been applied to establish and manage

the risk posed.While other serovars of verocytotoxigenic

E.coli(including E.coli O26, O111, O103, O145)

are now emerging as a cause of similar illness to E.coli

O157:H7 they are not addressed in this paper as there is

still limited information on their transmission thorough

the beef chain and they have not been included in any published

quantitative risk assessment models.2.E.coli O157:H7: human clinical aspects

E.coli O157 is a member of the Enterhaemorrhagic

group of E.coli(EHEC)and was first implicated in infectious

disease in the early 1980s(Riley et al., 1983).The

symptoms of infection include bloody diarrhoea and severe

abdominal pain.Haemolytic uraemic syndrome(HUS), a

cause of acute renal failure, may be a complication of the

illness, and neurological problems in the form of thrombotic

thrombocytopaenic purpura(TTP)may also occur.Immuno-compromised patients, including young children

and the elderly, are at particular risk of developing HUS.The time from exposure to onset of symptoms ranges fromto 14 days(Coia, 1998).However, with complications the

illness may last many months and lead to permanent damage

or even death.Pathogenicity is related to the ability of

the organism to adhere to and colonise the human large

intestinal epithelial tissue, forming attachment and effacing

(AE)lesions and the production of verocytotoxins.The

E.coli verocytotoxins are closely related to the Shiga toxin

of Shigella dysenteriae and are typically bacteriophage

encoded.There are two main classes of verotoxin: VT1, a

homogeneous group of toxins, virtually identical to the

Shiga toxin of Shigella and VT2, a heterogeneous group

of toxins, more distantly related to the Shiga toxin.E.coli O157 with the eae gene and VT2 are most often

associated with HUS in patients(Werber et al., 2003).Outbreaks of VTEC infections involving serovar O157

have now been reported from United States and Canada

Bell et al.(1994)(Lisbea), Asia(Michino et al., 1998), Australia

(Desmarchelier, 1996), Europe(Tozzi, Gorietti, &

Caprioli, 2001), and Africa(Germani, Soro, Vohito,Morel, & Morvan, 1997).However, the majority of cases

are sporadic and contribute significantly to overall cases

of infection.There is considerable variation in infection

rates between different geographical regions.In Europe, the

highest rates of infection are in Scotland with approximately 4 cases per 100,000(SCIEH, 2006).In the Republic of Ireland

the incidence per 100,000 has ranged from a peak of

2.2 in 2003 to 1.3 in 2004(HPSC, 2004).In Northern Europe

infection rates are very low ranging from 0.04 per

100,000 in Norway and Finland to 1.1 in Denmark in

2000 although Denmark has in 2006, reported its first general

outbreak of E.coli O157 attributed to contaminated

milk(Jensen et al., 2006).In 2004, the incidence rate for

E.coli O157:H7 in North America was 0.9, a drop from

1.1 cases in 2003.In Asia, Japan has experienced the most

problems related to E.coli O157:H7 with an average incidence

rate of 2.74 per 100,000 between 1999 and 2004

(Sakuma, Urashima, & Okabe, 2006).A number of sources

and reservoirs of E.coli O157 including beef and lamb,lettuce, sprouts, fruit juices, vegetables, raw milk, water

have been implicated as vehicles of transmission(Bell

et al., 1994;Cowden, Ahmed, Donaghy, & Riley, 2001;

Hilborn et al., 2000;Michino et al., 1999).Person-to-person

is also an important mode of transmission, particularly

in day care centers(O’Donnell et al., 2002)and direct contact

with animals carrying the organism or with faecally

contaminated mud(Anon, 1999;Crampin et al., 1999)

are also recognised sources of infection

第三篇：大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)

大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)

gkstk小編為大家搜集了一篇關(guān)于醫(yī)藥學(xué)專業(yè)大學(xué)生職業(yè)生涯規(guī)劃書，供大家參考借鑒。

一、藥學(xué)專業(yè)環(huán)境及評價

藥學(xué)專業(yè)的就業(yè)方向十分廣闊，與藥品相關(guān)的各個領(lǐng)域(主要包括藥品研究開發(fā)部門、生產(chǎn)部門、管理部門、營銷及使用部門)都需要藥學(xué)專業(yè)的畢業(yè)生。具體而言有醫(yī)院、科研院所、藥廠、醫(yī)藥藥學(xué)專業(yè)的就業(yè)方向十分廣闊，與藥品相關(guān)的各個領(lǐng)域(主要包括藥品研究開發(fā)部門、生產(chǎn)部門、管理部門、營銷及使用部門)都需要藥學(xué)專業(yè)的畢業(yè)生。具體而言有醫(yī)院、科研院所、藥廠、醫(yī)藥公司、國家藥品管理機(jī)關(guān)等單位。

藥學(xué)專業(yè)學(xué)生畢業(yè)后可從事一切與藥物有關(guān)的工作：

科研人員在研究所、藥廠的研究部門，從事藥物的研發(fā)工作;

醫(yī)院藥劑師在醫(yī)院藥劑科，從事制劑、質(zhì)檢、臨床藥學(xué)等工作;

藥檢人員在藥檢所從事藥物的質(zhì)量鑒定和制定相應(yīng)的質(zhì)量標(biāo)準(zhǔn);

公司職員在醫(yī)藥貿(mào)易公司或制藥企業(yè)從事藥品生產(chǎn)、流通及國內(nèi)外貿(mào)易公司、國家藥品管理機(jī)關(guān)

二、藥學(xué)專業(yè)的現(xiàn)狀及前景 #from 大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)來自 end#

據(jù)了解，藥學(xué)畢業(yè)生在選擇工作時主要考慮單位的發(fā)展方向和知名度、是否能給自己提供充足的發(fā)展空間、工作地點(diǎn)和薪酬水平。目前大學(xué)畢業(yè)生就業(yè)大環(huán)境普遍不好，他們的就業(yè)也日趨理性和務(wù)實。大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)。中國藥科大學(xué)學(xué)生工作處余永久處長說，學(xué)校結(jié)合市場需求，開設(shè)的專業(yè)和招生數(shù)量與人才需求基本吻合。學(xué)生更注重對自己動手能力的培養(yǎng)，能結(jié)合自己的專長，選擇適合的工作。

目前藥學(xué)類專業(yè)?？飘厴I(yè)生期望的月薪為15～XX元，本科生在3元左右，基本符合用人單位愿意支付的薪酬水平，但相比往年有所下降。就業(yè)選擇的結(jié)構(gòu)性矛盾突出表現(xiàn)在地域差別上。藥學(xué)類畢業(yè)生主要選擇在京、津、滬和浙、蘇、粵、魯?shù)难睾３鞘?、省會城市就業(yè)，而一些著名的大型藥企由于地域問題，很難招到滿意的人才。大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)文章大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)出自wk-78500000544146.html，此鏈接！。

三、藥學(xué)專業(yè)環(huán)境分析(職業(yè)生涯規(guī)劃swot分析法)

1.優(yōu)勢(strength)

我國醫(yī)院臨床藥學(xué)工作自8年開民以來，得到衛(wèi)生部的重視和支持，并將其工作作為評定醫(yī)院等級的一項重要內(nèi)容，因此在各地大醫(yī)院中工作開展得較好，在崗位方面，畢業(yè)生到制藥企業(yè)從事生產(chǎn)和銷售居多，這方面人才也是企業(yè)招聘的主體?，F(xiàn)在學(xué)醫(yī)藥方面的前景很好，目前隨著人們的生活水平在不斷的提高，會對醫(yī)療，保健方面的需求會大大增加.所以只要你的技術(shù)夠好，前景很好!

2.劣勢(weakness)

由于我國具體的國情和兩階段培養(yǎng)的藥師，在醫(yī)院中大多數(shù)仍在從事于調(diào)劑工作和藥品采購供應(yīng)以及從事于制劑生產(chǎn)，他們?nèi)狈詫嵉呐R床醫(yī)學(xué)和相關(guān)臨床知識，難以勝任臨床藥學(xué)工作，這與發(fā)達(dá)國家培養(yǎng)的藥師，在專業(yè)相關(guān)臨床知識方面差距基大，當(dāng)前由于經(jīng)濟(jì)利益的驅(qū)動，許多醫(yī)院領(lǐng)導(dǎo)只關(guān)心醫(yī)院的經(jīng)濟(jì)利益，因此，難以支持將藥劑科人力、財力投向臨床藥學(xué)，故影響了臨床藥學(xué)工作的廣泛深入發(fā)展，但是隨著醫(yī)療衛(wèi)生體制改革的進(jìn)行，藥劑科應(yīng)主動轉(zhuǎn)變觀念，積極推進(jìn)開展臨床藥學(xué)，在一些有條件的醫(yī)院積極推進(jìn)藥學(xué)監(jiān)護(hù)。藥學(xué)監(jiān)護(hù)的對象是所在患者，其工作目標(biāo)和達(dá)到的結(jié)果是為所有接受藥物治療的患者改善生命質(zhì)量和身心健康，保證其用藥的安全和有效承擔(dān)責(zé)任，而臨床藥學(xué)的工作對象，大多是住院病人和為臨床醫(yī)師提供各種監(jiān)測數(shù)據(jù)和資料信息，這些意見采綱與否取決于醫(yī)院和患者，此外，臨床藥學(xué)的工作目標(biāo)大多是某些種類的藥物和疾病狀態(tài)，所以其工作范圍有一定局限性。因此實施藥學(xué)監(jiān)護(hù)，必然要求藥師應(yīng)具有廣泛的知識能力，才能做好此項工作。

3.機(jī)遇(opportunity)

在全國就業(yè)形勢不容樂觀的情況下，藥科類畢業(yè)生的就業(yè)前景仍然普遍看好。醫(yī)藥英才網(wǎng)張美玲總經(jīng)理介紹說，總體來看，藥科類畢業(yè)生供小于求，各醫(yī)藥公司、制藥廠是吸收這類畢業(yè)生的大戶，制藥業(yè)對人才的需求是穩(wěn)中有升。據(jù)中國藥科大學(xué)、沈陽藥科大學(xué)、四川大學(xué)華西藥學(xué)院、北京大學(xué)醫(yī)學(xué)部藥學(xué)院就業(yè)工作負(fù)責(zé)人介紹，近幾年，這幾所學(xué)校的畢業(yè)生就業(yè)率接近1%，總體供需比達(dá)到1∶3～1∶4。大學(xué)生職業(yè)生涯規(guī)劃書醫(yī)藥學(xué)專業(yè)職業(yè)規(guī)劃。沈陽藥科大學(xué)學(xué)生工作處處長、就業(yè)辦公室主任劉彥介紹說，該校的市場營銷本科畢業(yè)生的供需比為1∶7，而藥物制劑、天然藥物化學(xué)等專業(yè)的研究生供需比甚至達(dá)到1∶1。目前從教學(xué)資源情況看，各學(xué)校都沒有擴(kuò)招計劃。對藥學(xué)畢業(yè)生來說是一個機(jī)會。

第四篇：醫(yī)藥學(xué)個人簡歷

個人簡歷

姓名：民族：聯(lián)系電話：畢業(yè)學(xué)校：專業(yè)：住址：電子信箱：

研究生導(dǎo)師：

執(zhí)業(yè)醫(yī)師資格證書：

教育及實習(xí)經(jīng)歷：

培訓(xùn)經(jīng)歷：

性別：出生年月：學(xué)歷：1

獲獎情況：

2010-2011

2004-2009

200

5擔(dān)任職務(wù)：

特長及興趣愛好：

在校期間，我參加了基礎(chǔ)部才藝?yán)夼_公益廣告大賽，獲得二等獎； 策劃并參加了“一二·九勿忘國恥”活動；策劃并參加了“考研宣講團(tuán)”活動，2011年“優(yōu)秀團(tuán)支部風(fēng)采大賽”，獲得一等獎。通過參加各種活動，我懂得了團(tuán)隊精神的重要性，也提高了我的組織協(xié)調(diào)能力。多年的校園生活養(yǎng)成了我樂觀向上，大方開朗，熱情務(wù)實，善于交流，待人誠懇，工作認(rèn)真，吃苦耐勞的精神。我愛好閱讀、運(yùn)動，也喜歡旅游。這些愛好讓我在忙碌緊張的學(xué)習(xí)之余調(diào)劑身心，勞逸結(jié)合，提高效率。

自我評價：

我出身于“中醫(yī)世家”，在家人的熏陶下立志做一名醫(yī)生，獻(xiàn)身于醫(yī)學(xué)事業(yè)！在校期間我學(xué)習(xí)刻苦，成績優(yōu)秀，掌握了扎實的醫(yī)學(xué)基礎(chǔ)理論知識和臨床技能。一年的臨床實習(xí)經(jīng)歷使我提高了分析問題、解決問題的能力。特別是獨(dú)立工作、獨(dú)立值夜班給我提供了許多實踐機(jī)會，增加了我的臨床經(jīng)驗，使我能更快速準(zhǔn)確的對臨床常見病做出診斷和治療。我熱愛“長春中醫(yī)藥大學(xué)”，是他孕育我成長，所以我希望成為長春中醫(yī)藥大學(xué)的一名醫(yī)生，為中醫(yī)藥大學(xué)的發(fā)展做出貢獻(xiàn)，為醫(yī)學(xué)事業(yè)奮斗終身。

第五篇：醫(yī)藥學(xué)名詞

二、名詞術(shù)語

醫(yī)學(xué)及藥學(xué)名詞應(yīng)使用全國自然科學(xué)名詞審定委員會公布的規(guī)范名詞（科學(xué)出版社出版）為準(zhǔn)。

1.現(xiàn)將常易出錯的不規(guī)范名詞糾正如下（括號中為不規(guī)范名詞）。

氨基酸轉(zhuǎn)移酶（轉(zhuǎn)氨酶）細(xì)胞（白血球）紅細(xì)胞（紅血球）

作用機(jī)制（機(jī)理）側(cè)支循環(huán)（側(cè)枝循環(huán)）綜合征（綜合癥）

膽固醇（膽甾醇）單核－吞噬細(xì)胞系統(tǒng)（網(wǎng)狀內(nèi)系統(tǒng)）

低鉀血癥（低血鉀癥）高脂血癥（高血脂癥）內(nèi)鏡（內(nèi)窺鏡）

固醇（甾醇）發(fā)紺（紫紺）反胃（返胃）

分枝桿菌（分支桿菌）肺源性（肺原性）肺梗死（肺梗塞）

腦出血（腦溢血）腦梗死（腦梗塞）心肌梗死（心肌梗塞）

腦卒中（中風(fēng)）放射性核素（同位素）功能（機(jī)能）

肝硬化（肝硬變）核糖體（核蛋白體）晶狀體（晶體）

膠原纖維（膠元纖維）假膜（偽膜）咳痰（咯痰）

咯血（咳血）抗生素（抗菌素）磷脂酰膽堿（卵磷脂）

黏膜（粘膜）清蛋白（白蛋白）期前收縮（早博）

妊娠高血壓綜合征（妊娠中毒癥）三酰甘油（甘油三脂）

腎衰竭（腎功能衰竭）食欲缺乏（食欲不振）食管（食道）

嗜酸（堿）性細(xì)胞（嗜酸（堿）性白細(xì)胞）同工酶（同功酶）

糖原（糖元）畏食（厭食）糖皮質(zhì)激素（糖皮質(zhì)類固醇）

圍生期（圍產(chǎn)期）下丘腦（丘腦下部）心排出量（心輸出量）

心源性（心原性）血紅蛋白（血色素）血流動力學(xué)（血液動力學(xué)）

藥源性（藥原性）醫(yī)源性（醫(yī)原性）真菌（霉菌）

原發(fā)性高血壓（高血壓）